US contract research organisation (CRO) Medpace is opening a 50-bed, 24-hour clinical pharmacology unit in Cincinnati, Ohio – site of the company’s global headquarters – that will “uniquely” focus on studies in defined metabolic patient populations.
The new Medpace Clinical Pharmacology Unit (Medpace CPU) is a Phase I/IIa trial facility for confined or controlled pharmacokinetic/pharmacodynamic studies using human volunteers, with first-in-man capability.
In line with the CRO’s approach of providing therapeutically focused clinical development services, Medpace’s dedicated subject recruitment division will leverage its strategic partnership with Cincinnati’s Metabolic and Atherosclerosis Research Center to recruit targeted patient populations including diabetics (Types I and II) and patients with metabolic syndromes or cardiovascular disease.
“Unprecedented in the region for its size and state-of-the-art equipment”, the Medpace CPU is located across the street from the Medpace Reference Laboratories, a full-service central laboratory featuring therapeutically specialised testing, the CRO noted.
Medpace believes its therapeutic expertise in cardiovascular, oncology and metabolic trials will stand out in a marketplace that “has a high demand for Phase I and II studies but rarely specialises in a few areas of focus”, commented chief executive officer Dr August Troendle.
